Biogen Earnings Beat Street - TheStreet
Links shared publicly online about this topic.
- 773total visits
Biogen Earnings Beat Street - TheStreet
View full resource at thestreet.com
Tags: Multiple Sclerosis, Multiple Sclerosis Medication, Drug, Avonex
Most Recently Shared on October 26, 2010 at 2:04 pm By:
Biogen Earnings Beat Street: Biogen reported higher third-quarter earnings on strong sales of its multiple scleros... http://bit.ly/aUSivM
LinkedIn profit beats expectations of net loss
sfgate.com — “LinkedIn may have boosted the fortunes of the entire social-networking sector Thursday when the Mountain View firm surprised Wall Street by reporting a profit in its first-ever earnings report as a public company. Some...” View full resource at sfgate.com
Most Recently Shared on August 5, 2011 at 1:17 pm By:
LinkedIn profit beats expectations of net loss http://sfg.ly/rdzFCW
Johnson & Johnson Beats Estimates, Profit Falls On Domestic Recalls - Heather Struck - Market Pulse - Forbes
blogs.forbes.com — “Johnson & Johnson, one of the world’s largest health-care companies, said its second-quarter profit dropped almost 20% from a year ago, as recall costs and restructuring charges offset sales during the quarter. The decline was expected, however, as the earnings came in above the street’s expectations. Earnings came in at $2.8 [...]” View full resource at blogs.forbes.com
Most Recently Shared on July 19, 2011 at 2:25 pm By:
Drugs and Devices OW OW Health
Johnson & Johnson Beats Estimates, Profit Falls On Domestic Recalls: Johnson & Johnson, one of the worl... http://onforb.es/pMzcyy #drug
Hospira's $1B buyback joins Big Pharma trend - FiercePharma
fiercepharma.com — “Along with Street-beating earnings, Hospira has announced that its board has approved a $1 billion stock-buyback plan. It's Hospira's second buyback program ever, with the $400 million plan Read more...” View full resource at fiercepharma.com
Most Recently Shared on April 26, 2011 at 2:56 pm By:
Hospira's $1B buyback joins Big Pharma trend. http://bit.ly/egsYq5
Biogen's Scangos earns Icahn's (rare) blessing - FierceBiotech
fiercebiotech.com — “The new CEO at Biogen Idec, George Scangos, just won a key vote of confidence from one of the prickliest investors on Wall Street. For the first time in four years Carl Icahn isn't trying to wrest Read more...” View full resource at fiercebiotech.com
Most Recently Shared on March 29, 2011 at 3:13 pm By:
Biogen's Scangos earns Icahn's (rare) blessing. http://bit.ly/efLVFP
Stupid Cancer Street Team Sign Up
stupidcancer.fancorps.com — “Join The Team Now. IT'S FREE!” View full resource at stupidcancer.fancorps.com
Most Recently Shared on March 16, 2011 at 2:59 pm By:
Matthew Zachary Patient Expert
Can't beat promoting @stupidcancer on @Fancorps and earning rewards for it! #stupidcancer. JOIN NOW: http://soc.li/axq5feL
Earnings Alert: Life Time Fitness is Expected to Beat the Street Consensus When It Reports Earnings (LTM) | Comtex SmarTrend
mysmartrend.com — “Earnings Alert: Life Time Fitness is Expected to Beat the Street Consensus When It Reports Earnings (LTM) | Comtex SmarTrend” View full resource at mysmartrend.com
Most Recently Shared on October 10, 2010 at 8:49 pm By:
Earnings Alert: Life Time Fitness is Expected to Beat the Street Consensus ... http://bit.ly/dhaTj9
Abbott sales rise 15% as Elan loss shrinks - FiercePharma
fiercepharma.com — “Another day, another slew of earnings reports. Today, it's Abbott Laboratories beating the Street's expectations, and Gilead Sciences posting a big increase in earnings. Here are the high points.... Read more...” View full resource at fiercepharma.com
Most Recently Shared on April 21, 2010 at 6:26 pm By:
Pharma earnings: Abbott sales rise 15% as Elan loss shrinks. http://is.gd/bCoUs
Advertisement
